RCT in 139 evaluable patients on oxaliplatin-, irinotecan- or carboplatin-based chemotherapy: adding olanzapine 5 mg to ondansetron and dexamethasone did not significantly improve total protection (71.0% vs 55.7% placebo, p=0.06); total control was higher (secondary).
RCTn = 139 patients
Harikul et al. A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy